Effect of Early-Life Fluoxetine on Anxiety-Like Behaviors in BDNF Val66Met Mice.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29084453.
- Also identified by DOI 10.1176/appi.ajp.2017.15121592 and PMC identifier 5711544.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adolescence is a developmental stage in which the incidence of psychiatric disorders, such as anxiety disorders, peaks. Selective serotonin reuptake inhibitors (SSRIs) are the main class of agents used to treat anxiety disorders. However, the impact of SSRIs on the developing brain during adolescence remains unknown. The authors assessed the impact of developmentally timed SSRI administration in a genetic mouse model displaying elevated anxiety-like behaviors. Knock-in mice containing a common human single-nucleotide polymorphism (Val66Met; rs6265) in brain-derived neurotrophic factor (BDNF), a growth factor implicated in the mechanism of action of SSRIs, were studied based on their established phenotype of increased anxiety-like behavior. Timed administration of fluoxetine was delivered during one of three developmental periods (postnatal days 21-42, 40-61, or 60-81), spanning the transition from childhood to adulthood. Neurochemical and anxiety-like behavioral analyses were performed. We identified a "sensitive period" during periadolescence (postnatal days 21-42) in which developmentally timed fluoxetine administration rescued anxiety-like phenotypes in BDNF Val66Met mice in adulthood. Compared with littermate controls, BDNF<sup>Met/Met</sup> mice exhibited diminished maturation of serotonergic fibers projecting particularly to the prefrontal cortex, as well as decreased expression of the serotonergic trophic factor S100B in the dorsal raphe. Interestingly, deficient serotonergic innervation, as well as S100B levels, were rescued with fluoxetine administration during periadolescence. These findings suggest that SSRI administration during a "sensitive period" during periadolescence leads to long-lasting anxiolytic effects in a genetic mouse model of elevated anxiety-like behaviors. These persistent effects highlight the role of BDNF in the maturation of the serotonin system and the capacity to enhance its development through a pharmacological intervention.
Medical subject headings
- Age Factors
- Animals
- Anti-Anxiety Agents
- Anti-Anxiety Agents/pharmacology
- Anti-Anxiety Agents/therapeutic use
- Anxiety
- Anxiety/drug therapy
- Anxiety/genetics
- Brain-Derived Neurotrophic Factor
- Brain-Derived Neurotrophic Factor/genetics
- Dorsal Raphe Nucleus
- Dorsal Raphe Nucleus/drug effects
- Dorsal Raphe Nucleus/metabolism
- Eating
- Eating/drug effects
- Fear
- Fear/drug effects
- Fluoxetine
- Fluoxetine/pharmacology
- Fluoxetine/therapeutic use
- Gene Knock-In Techniques
- Male
- Maze Learning
- Maze Learning/drug effects
- Mice
- Polymorphism, Single Nucleotide
- Polymorphism, Single Nucleotide/genetics
- Prefrontal Cortex
- Prefrontal Cortex/drug effects
- S100 Calcium Binding Protein beta Subunit
- S100 Calcium Binding Protein beta Subunit/metabolism
- Serotonergic Neurons
- Serotonergic Neurons/drug effects
- Selective Serotonin Reuptake Inhibitors
- Selective Serotonin Reuptake Inhibitors/pharmacology
- Selective Serotonin Reuptake Inhibitors/therapeutic use